Gamida Cell Ltd.
Harey Yehuda 54
P.O.B. 94
Savyon
56530
Tel: 03-534-7482
Fax: 03-534-3067
218 articles about Gamida Cell Ltd.
-
Gamida Cell Announces Data to Be Presented at 63rd ASH Annual Meeting
11/4/2021
Gamida Cell Ltd., an advanced cell therapy company committed to cures for cancer and other serious diseases, announced four presentations at the 63rd American Society of Hematology Annual Meeting, which is being held in Atlanta, Georgia or virtually from December 11-14, 2021.
-
Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today’s Virtual R&D Day
10/26/2021
Gamida Cell to Present NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline and Update on GDA-201 at Today’s Virtual R&D Day
-
Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
10/19/2021
Gamida Cell to Present at Society for Immunotherapy of Cancer's (SITC) 36 th Annual Meeting
-
Gamida Cell to Host Virtual Event Highlighting GDA-201 and NAM-Enabled, Genetically Modified NK Cell Therapy Pipeline
9/28/2021
Gamida Cell Ltd. today announced that it will host a virtual event detailing the company’s proprietary NAM-enabled natural killer (NK) cell therapy pipeline on Tuesday, October 26, 2021 at 8:00 a.m. ET.
-
Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in September 2021
9/2/2021
Gamida Cell Ltd., an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced that company management will present its corporate highlights at the following virtual investor conferences in September.
-
Gamida Cell Reports Second Quarter 2021 Financial Results and Provides Company Update
8/11/2021
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today reported financial results for the quarter ended June 30, 2021.
-
Gamida Cell Announces the Date of Its Second Quarter 2021 Financial Results and Webcast
8/4/2021
Gamida Cell Ltd. today announced that the company will host a conference call and live audio webcast on Wednesday, August 11, 2021, at 8:00 a.m. ET to review its second quarter 2021 financial results and provide an update on the company.
-
Gamida Cell to Present at the BTIG Virtual Biotechnology Conference
8/3/2021
Gamida Cell Ltd. today announced that the company will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 10, 2021 at 3:00 p.m. ET.
-
Gamida Cell Announces Publication in Blood, the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel)
6/23/2021
Gamida Cell Announces Publication in Blood , the Journal of the American Society of Hematology, of the First Pivotal Trial to Evaluate a Cell Therapy (Omidubicel) for Patients with Blood Cancer who Require an Allogeneic Stem Cell Transplant
-
Gamida Cell to Present Corporate Highlights at Multiple Investor Conferences in June
6/9/2021
Gamida Cell Ltd. today announced that company management will present its corporate highlights at the following investor conferences in June.
-
Gamida Cell Announces Appointment of Senior Vice President, Global Operations and Manufacturing and Provides Commercial Manufacturing Update
6/7/2021
Gamida Cell Ltd., an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced the appointment of Vladimir Melnikov as senior vice president, global operations and manufacturing.
-
Gamida Cell to Present at the RBC Capital Markets Global Healthcare Conference
5/12/2021
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that Julian Adams, Ph. D., chief executive officer of Gamida Cell, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 3:40 p.m. ET.
-
Gamida Cell Reports First Quarter 2021 Financial Results and Provides Company Update
5/11/2021
BLA submission for omidubicel, a potentially life-saving treatment for patients with blood cancers in need of stem cell transplant, expected in fourth quarter of 2021 Pre-commercial and manufacturing activities underway to support potential launch of omidubicel in 2022 Phase 1/2 clinical trial of allogeneic, off-the-shelf GDA-201 in NHL planned with IND submission anticipated in the second half of 2021
-
Gamida Cell Announces the Date of Its First Quarter 2021 Financial Results and Webcast
5/4/2021
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, May 11, 2021, at 8:00 a.m. ET to review its first quarter 2021 financial results and provide an update on the company.
-
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
3/15/2021
Gamida Cell Presents Efficacy and Safety Results of Phase 3 Study of Omidubicel in Patients with Hematologic Malignancies at the 47 th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) -Abstract will be shared at Presidential Symposium and featured in this year’s “Live with Best Abstracts” session-
-
Gamida Cell Reports Full Year 2020 Financial Results and Provides Company Update
3/9/2021
– Primary and secondary endpoints were met, key exploratory endpoints supported clinical benefit in Phase 3 study of omidubicel in patients with hematologic malignancies; BLA submission anticipated in fourth quarter of 2021- — Omidubicel commercial preparation underway, including the creation of Gamida Cell Assist, to support potential launch —
-
Gamida Cell to Present at Upcoming Investor Conferences
3/3/2021
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, announced today that company management will participate in two upcoming investor conferences in March: H.C. Wainwright Global Life Sciences Conference, March 10, 2021. Company presentation will be available for on-demand viewing at 7:00 a.m. ET on Tuesday, March 9, 2021.
-
Gamida Cell Announces the Date of Its Full Year 2020 Financial Results and Webcast
3/2/2021
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a conference call and live audio webcast on Tuesday, March 9, 2021, at 8:30 a.m. ET to review its full year 2020 financial results and provide an update on the company.
-
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
3/1/2021
Gamida Cell Announces Results from Phase 3 Study of Omidubicel to be Presented at the 47 th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)
-
Gamida Cell Announces $75 Million Financing with Highbridge Capital Management
2/16/2021
Pro forma Cash Expected to Fund Manufacturing, Regulatory and Commercial Readiness Preparations for Omidubicel and the Advancement of GDA-201 Clinical Development